Identification of novel inhibitor targeting Fyn kinase using molecular docking analysis.

Identification of novel inhibitor targeting Fyn kinase using molecular docking analysis. Bioinformation. 2019;15(6):419-424 Authors: Nedunchezhian D, Langeswaran K, Santhoshkumar S Abstract Identification of tyrosine Fyn kinase inhibitor is recognized as an effective and feasible therapeutic measure in reducing consequences of memory loss disorder Alzheimer's. The present investigation has been attempted with an objective to find out a novel potent inhibitor with similar homological structure to Fyn kinase using structure based in silico screening measure. Such derived structure was compared with natural data base pool and were systematically analyzed. Ligand based interaction was also tested and evaluated. We applied a molecular dynamic simulation technique to validate the stability of the identified complexes and to understand the ligand binding mechanism. Results provide information on the characteristics of novel and potent inhibitor for tyrosinase Fyn kinase protein so as to develop an innovative strategy to treat AD. PMID: 31312079 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research

Related Links:

Abstract Alzheimer's disease (AD) is associated with multifactorial neuropathological conditions, which include cholinergic deficit, amyloid-beta plaques formation, loss of neuronal plasticity and neuronal death. Treating such multifactorial conditions with a single target directed approach is considered to be inadequate. Accordingly, multi-target directed ligand (MTDL) strategy has been evolved as an auspicious approach for the treatment of AD. In light of that, a library of 2-substituted benzo[d]oxazol-5-amine derivatives (29-39; 86-107) was designed using the scaffold hopping guided MTDLs strategy, synthesized ...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Gradual memory loss, cognitive decline, wandering off to unknown places, being unable to dress in the morning: to live with dementia and Alzheimer’s disease might be a heart-wrenching burden for both patients and their loved ones. As the global population ages, and the number of individuals suffering from these conditions rises, digital technologies must step forward and offer some solutions for early detection and disease management. That’s what we examined in detail here, so let’s see the intersections of digital health and Alzheimer’s disease. Have you seen Aurora Borealis? Your mind can pl...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine alzheimer Alzheimer's disease brain cognitive health dementia digital digital health elderly elderly care Healthcare Innovation medical technology Source Type: blogs
Abstract The aim of the present study was to assess thealterations of corticolimbic microRNAs and protein expressions in the effect of scopolamine with or without stress on passive-avoidance memory in male Wistar rats. The expressions of miR-1, miR-10 and miR-26 and also the levels of p-CREB, CREB, C-FOS and BDNF in the prefrontal cortex (PFC), the hippocampus and the amygdala were evaluated using RT-qPCR and Western blotting techniques. The data showed that the administration of a muscarinic receptor antagonist, scopolamine or the exposure to 30 min stress significantly induced memory loss. Interestingly, the inj...
Source: Neurobiology of Learning and Memory - Category: Neurology Authors: Tags: Neurobiol Learn Mem Source Type: research
Preliminary results from biotech startup Alkahest claim that Alzheimer's patients who got a drug made from young blood plasma showed no or far less mental decline than expected for six months.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conclusion:We reported a probably novel mutation in exon 5 of the presenilin 1 gene (Gln222Leu) in a Chinese family with early-onset Alzheimer's disease , besides,we predicted that the missense mutation was probably a novel pathogenic mutation that was reported for the first time in Chinese family with early-onset Alzheimer's disease. PMID: 31385772 [PubMed - as supplied by publisher]
Source: Current Alzheimer Research - Category: Neurology Authors: Tags: Curr Alzheimer Res Source Type: research
In this study, the team took samples from 158 people over the age of 50, most of whom were cognitively normal at the start of the study, and followed them for about four years to see which participants developed Alzheimer’s. To verify the amyloid levels found in the blood test, the volunteers also had a PET scan of their brains and provided samples of cerebrospinal fluid, near the start and then again near the end of the study period. The blood samples were collected within 18 months of the first amyloid PET scan, and 88% of the time, the blood test matched the scan. That’s not accurate enough to use as a test ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Alzheimer's Brain embargoed study Source Type: news
THURSDAY, Aug. 1, 2019 -- A simple blood test helped pinpoint the early signs of Alzheimer's in a new study. Up to two decades before people develop Alzheimer's symptoms such as memory loss and confusion, harmful clumps of amyloid beta protein begin...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
"...Whereas once an aging relative who became "senile" was whisked off to the back bedroom when company came, now we arrange museum visits and special theater performances for those with memory loss and other cognitive issues. Celebrities such as musician Glen Campbell and basketball coach Pat Summitt have gone public with their Alzheimer's diagnoses, making it somewhat easier for others to have the courage to come forward." Read more on HealthCentral about the challenges or making an Alzheimer's or other dementia diagnosis public: Carol Bradley Bursack is the Candid Caregiver MedicareFAQ – Medica...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
Ginkgo biloba extract, derived from the leaves of the Ginkgo biloba tree, is often touted as a memory aid. But it appears unlikely that Ginkgo biloba extract can slow or prevent age-related memory problems, or memory loss associated with mild cognitive impairment or Alzheimer's disease. Several small, early studies showed modest improvements in cognitive function for older [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
Rubrofusarin inhibits Aβ aggregation and ameliorates memory loss in an Aβ-induced Alzheimer's disease-like mouse model. Food Chem Toxicol. 2019 Jul 23;:110698 Authors: Cho E, Cai M, Kwon H, Jeon J, Moon M, Jun M, Lee YC, Yi JH, Ryu JH, Kim DH Abstract The misfolding and aggregation of amyloid β (Aβ) peptide is a common histopathologic characteristic in patients with Alzheimer's disease, so is considered to play an critical role. In the present study, we examined the effect of rubrofusarin, an ingredient of Cassiae semen, on Aβ aggregation and memory loss in an AD mouse model. ...
Source: Food and Chemical Toxicology - Category: Food Science Authors: Tags: Food Chem Toxicol Source Type: research
More News: Alzheimer's | Amnesia | Bioinformatics